Intellia Therapeutics, Inc. NTLA
Set alert
12.31 USD +0.65 +5.54%
As of Nov 3, 10:36 AM ET
11.73 Day range 12.39
7.95 52-week range 18.48
- YTD
- +36.88%
- 1 year
- -5.85%
- Open
- 11.73
- Prev close
- 11.66
- Mkt cap
- 1.72B
- Vol
- 559.28K
- Avg vol
- 4.39M
- EPS
- -3.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.73
- High
- 12.39
- Forward P/E
- -4.55
- Beta
- 1.82
- Short ratio
- 7.63
- Inst. own
- 100.56%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 12.23
- 200-d avg
- 13.08
- 1y target
- 23.11
Analyst view
Consensus: none
Price target (mean) 23.11 +87.8% upside
Now 12.31
- Target (low)
- 8.00
- Target (mean)
- 23.11
- Target (high)
- 61.00
Ratings (0m) 20 10 buy · 6 hold · 4 sell
- Strong buy1
- Buy9
- Hold6
- Sell2
- Strong sell2
Recommendation trend
- This month 20
- 1 month ago 19
- 2 months ago 19
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.78559 | -0.89 – -0.71 | -0.92 | +14.6% | 9.77M | -29.1% | 16 |
| Next quarter | -0.75096 | -0.91 – -0.41 | -0.83 | +9.5% | 17.09M | -25.8% | 16 |
| Current year | -3.14 | -3.41 – -2.83 | -3.81 | +17.5% | 51.88M | -23.3% | 17 |
| Next year | -2.56 | -3.62 – 0.97 | -3.14 | +18.4% | 126.26M | +143.4% | 17 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 2026 | Barclays | Initiated | — | Underweight |
| Sep 9, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Sep 9, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Sep 9, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 25, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Aug 7, 2026 | Evercore ISI Group | Upgrade | In-Line | Outperform |
| Jul 16, 2026 | Wolfe Research | Downgrade | Peer Perform | Underperform |
| Jul 10, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Jun 16, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 15, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Jun 15, 2026 | Wedbush | Reiterated | Neutral | Neutral |
| Jun 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 13, 2026 | Bernstein | Maintained | Market Perform | Market Perform |
| May 13, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 12, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| May 12, 2026 | Wedbush | Reiterated | Neutral | Neutral |
| Apr 28, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Apr 28, 2026 | Goldman Sachs | Maintained | Sell | Sell |
| Apr 28, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Apr 28, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Apr 27, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Apr 27, 2026 | Baird | Maintained | Neutral | Neutral |
| Mar 4, 2026 | Jones Trading | Upgrade | Hold | Buy |
| Mar 3, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 3, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Mar 3, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Mar 3, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Mar 3, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Mar 3, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 2, 2026 | Chardan Capital | Maintained | Buy | Buy |